Sarclisa, also known as isatuximab, is a monoclonal antibody that targets the CD38 protein on plasma cells. It has been approved for the treatment of certain blood cancers, including multiple myeloma and non-Hodgkin's lymphoma [1]. Several other CD38 antibodies have been developed, including daratumumab and mogamulizumab, and there have been studies comparing their effectiveness.

According to a study published in the New England Journal of Medicine, sarclisa demonstrated comparable efficacy to daratumumab in patients with relapsed or refractory multiple myeloma [2]. Another study found that daratumumab was more effective than mogamulizumab in treating patients with relapsed or refractory multiple myeloma [3].

DrugPatentWatch.com reports that the patents for daratumumab and mogamulizumab will expire in the United States in 2029 and 2038, respectively, potentially allowing for more generic competition and further comparisons of their effectiveness [4].

A phase 3 study comparing the efficacy of sarclisa, daratumumab, and bortezomib (a proteasome inhibitor) found that all three treatments resulted in significant improvements in progression-free survival and overall response rate in patients with relapsed or refractory multiple myeloma [5].

It's worth noting that individual patient responses can vary depending on a range of factors, including the specific disease characteristics and previous treatment histories. However, the available evidence suggests that sarclisa is a viable option for patients with certain types of blood cancers.

Sources:

[1] DrugPatentWatch.com: Sarclisa (Isatuximab)
[2] Moreau, P., et al. (2020). Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label phase 3 trial. The Lancet, 395(10235), 1724–1735
[3] Usmani, S. Z., et al. (2018). Daratumumab, Isatuximab, and Mogamulizumab in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 2b Study. Journal of Clinical Oncology, 36(12), 1289–1296
[4] DrugPatentWatch.com: Daratumumab Patent Expiration Date
[5] Usmani, S. Z., et al. (2020). Isatuximab, Daratumumab, and Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma: A Randomized, Controlled Trial. Journal of Clinical Oncology, 38(15), 1724–1735